14-day Premium Trial Subscription Try For FreeTry Free
$177.71
-0.0700 (-0.0394%)
At Close: Jun 17, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Krystal Biotech Inc Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -67.60. In total, the insiders bought 51 800 and sold 265 300 KRYS shares in the last 100 trades.

Insider Power

(Last 100 transactions) 		-67.60
Buy 51 800 Shares
Sell 265 300 Shares

Historical Insider Trades

Date Type Action Person Amount
Jun 11, 2024 Common Stock Sell Krishnan Suma 1 100
Jun 11, 2024 Common Stock Sell Krishnan Suma 1 882
Jun 11, 2024 Common Stock Sell Krishnan Suma 1 318
Jun 11, 2024 Common Stock Sell Krishnan Suma 4 000
Jun 11, 2024 Common Stock Sell Krishnan Suma 4 550
Jun 11, 2024 Common Stock Sell Krishnan Suma 5 705
Jun 11, 2024 Common Stock Sell Krishnan Suma 5 447
Jun 11, 2024 Common Stock Sell Krishnan Suma 998
Jun 11, 2024 Common Stock Sell Krishnan Suma 900
Jun 11, 2024 Common Stock Sell Krishnan Suma 2 099
Jun 11, 2024 Common Stock Sell Krishnan Suma 1 206
Jun 11, 2024 Common Stock Sell Krishnan Suma 1 724
Jun 11, 2024 Common Stock Sell Krishnan Suma 4 975
Jun 11, 2024 Common Stock Sell Krishnan Suma 5 867
Jun 11, 2024 Common Stock Sell Krishnan Suma 6 358
Jun 11, 2024 Common Stock Sell Krishnan Suma 1 871
Jun 11, 2024 Common Stock Sell Krishnan Krish S 1 100
Jun 11, 2024 Common Stock Sell Krishnan Krish S 1 882
Jun 11, 2024 Common Stock Sell Krishnan Krish S 1 318
Jun 11, 2024 Common Stock Sell Krishnan Krish S 4 000
Jun 11, 2024 Common Stock Sell Krishnan Krish S 4 550
Jun 11, 2024 Common Stock Sell Krishnan Krish S 5 705
Jun 11, 2024 Common Stock Sell Krishnan Krish S 5 447
Jun 11, 2024 Common Stock Sell Krishnan Krish S 998
Jun 11, 2024 Common Stock Sell Krishnan Krish S 900
Click to get the best stock tips daily for free!

About Krystal Biotech Inc

Krystal Biotech Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive con... KRYS Profile

Golden Star

Ticker Date Change Price
MAIN Jun 13 0.85% $49.14
AMP Jun 13 1.32% $426.91
RSG Jun 13 2.27% $187.43
NSIT Jun 13 1.55% $198.39
BNDX Jun 13 0.0820% $48.80
ESGE Jun 13 0.85% $33.13
EMXC Jun 13 0.87% $57.80
LIN Jun 12 1.49% $434.17
XBIL Jun 12 0.0500% $49.97
EQR Jun 11 2.23% $65.55
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT